Nvidia: A cheap chip-maker
This stock trades at a low price-to-earnings ratio and carries $6 a share on its balance sheet.
By Ian Wyatt, Top Stock Insights
Nvidia (NVDA) has been on a steady retreat since topping near $15 in August. In fact, the recent selling is only part of a much larger decline. NVDA was a $25 stock in early 2011.
Nvidia is a major supplier of the graphics chips inside PCs. So a decline in PC demand hurts its business. As a result, the stock has been dragged lower during the past two years because PC sales have flat-lined. But Wall Street seems to have forgotten that the company branched out beyond PCs. Their graphics cards, specifically Tegra and Icera, are in mobile devices -- including Google's (GOOG) Nexus and Microsoft's (MSFT) SurfaceRT. (Microsoft owns and publishes Top Stocks, an MSN Money site.)
This segment of Nvidia is expected to grow sales by 50% in 2013. Moreover, Texas Instruments (TXN) exited the tablet industry, paving the way for another company to supply graphics processors for the Amazon.com (AMZN) Kindle lineup.
In addition to the future growth opportunities from mobile and handhelds, Nvidia has an amazing balance sheet. The company boasts more than $3.75 billion in cash and investments with almost zero debt ($20 million).
This cash balance also enabled the company to initiate a 2.5% dividend this year. Furthermore, that cash balance equates to nearly $6 per share and takes the company's enterprise value down to about $4 billion.
Analysts expect the company to report earnings per share of $0.86 this year, giving the stock a price-to-earnings ratio of 14. However, if we take out the cash and recalculate, the ratio declines to seven.
Nvidia may not be the growth juggernaut it was in the past. However, it's transitioning into growing segments and gaining market share, too.
Additionally, the shares are unbelievably cheap now, trading at seven times the enterprise value. We believe the stock could soar to $17 next year, and any price that's below $14.50 provides you with a great entry.
More from TheStockAdvisors.com
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Puma Biotechnology shares soar after it says it wants to file for marketing approval of an experimental breast cancer drug.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.